Lexeo Therapeutics · 1 month ago
Senior Medical Science Liaison (MSL) - Field/HQ Hybrid Role
New York, New York
Full-time
Hybrid
Mid, Senior Level
3+ years expLexeo Therapeutics is a clinical-stage genetic medicine company pioneering cardiac genetic medicine candidates. The Senior Medical Science Liaison (MSL) will contribute to both key field-based and HQ Medical Affairs initiatives, shaping the scientific landscape for gene therapy programs and collaborating with cross-functional teams.
BiotechnologyLife ScienceTherapeutics
Responsibilities
Leverage scientific expertise to establish and maintain strategically impactful relationships with national, regional, and local Key Opinion Leaders (KOLs) and other healthcare providers (HCPs) for Lexeo’s cardiac gene therapy pipeline, in alignment with medical strategy
Proactively and reactively engage KOLs and HCPs on various topics, including disease state education, mechanism of action, emerging and existing clinical data, and the evolution of treatment landscapes for Lexeo’s cardiac gene therapy pipeline
Support asset-specific pre-launch readiness and optimize launch execution through the attainment of impactful field medical metrics
Provide internal stakeholders with actionable medical insights gathered from scientific interactions with HCPs
Explore new areas of scientific and clinical interest to understand unmet needs, how the landscape is evolving, and how Lexeo’s pipeline programs may address those needs
Collaborate with Clinical Development and Clinical Operations to support clinical trial sites and investigators as needed
Stay current on medical and scientific developments in related therapeutic areas by continuously reviewing literature, monitoring competitor activities, networking with experts, and attending assigned scientific congresses and symposia
Complete accurate and timely administrative responsibilities, including reports, projects, and required documentation
Deliver approved medical and scientific presentations to internal and external stakeholders
Support evidence generation efforts by facilitating external investigator-sponsored research (ISR) concept submissions
Regularly collaborate with field-based and cross-functional colleagues to advance clinical practice in a compliant manner
Support medical and scientific training of cross-functional teams as needed
Adhere to Lexeo Therapeutics’ values, culture, and policies
Qualification
Required
MD, DO, PhD, PharmD, other doctorate degrees relevant to the role, RPh, NP, PA, other APPs, and/or a Master's degree in life sciences with clinical research experience in neuromuscular or cardiac disease
3+ years of field experience in the biotech or pharmaceutical industry, OR 2+ years and launch experience, OR direct patient care experience in cardiology or neurology
Ability to interpret key scientific data and translate findings to meet educational and research needs
Strong interpersonal, presentation, and communication skills, and demonstrated ability to work collaboratively in a dynamic, fast-paced, team-oriented environment
Preferred
Gene therapy experience preferred, particularly in the neuromuscular space
Company
Lexeo Therapeutics
LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.
11-50 employees
H1B Sponsorship
Lexeo Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2024 (1)
2022 (2)
2021 (1)
Funding
Current Stage
Public CompanyTotal Funding
$514MKey Investors
Balyasny Asset ManagementSarepta Therapeutics
2025-10-16Post Ipo Equity· $154M
2025-05-27Post Ipo Equity· $80M
2024-03-11Post Ipo Equity· $95M
Leadership Team
R. Nolan Townsend
Chief Executive Officer
Louis Tamayo
Chief Financial Officer
Recent News
BioWorld Financial Watch
2026-01-16
2026-01-13
Company data provided by crunchbase